tradingkey.logo

Lifeward Ltd

LFWD
0.544USD
-0.009-1.68%
Market hours ETQuotes delayed by 15 min
8.52MMarket Cap
LossP/E TTM

Lifeward Ltd

0.544
-0.009-1.68%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Lifeward Ltd

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lifeward Ltd's Score

Industry at a Glance

Industry Ranking
127 / 210
Overall Ranking
270 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.500
Target Price
+845.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lifeward Ltd Highlights

StrengthsRisks
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.66M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 25.66M.
Overvalued
The company’s latest PE is -0.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 455.00K shares, decreasing 71.72% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 91.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.66.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.31, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 5.72M, representing a year-over-year decrease of 14.66%, while its net profit experienced a year-over-year decrease of 52.46%.

Score

Industry at a Glance

Previous score
6.31
Change
0

Financials

6.14

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.10

Operational Efficiency

5.39

Growth Potential

5.80

Shareholder Returns

7.11

Lifeward Ltd's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.18, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.18, which is -4.27% below the recent high of -0.17 and -11101.25% above the recent low of -19.69.

Score

Industry at a Glance

Previous score
8.18
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 127/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Lifeward Ltd is 5.50, with a high of 10.00 and a low of 1.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.500
Target Price
+845.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Lifeward Ltd
LFWD
2
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 5.54, which is lower than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 0.75 and the support level at 0.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
5.16
Change
0.38

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.033
Sell
RSI(14)
29.377
Sell
STOCH(KDJ)(9,3,3)
7.707
Oversold
ATR(14)
0.043
Low Volatility
CCI(14)
-204.114
Oversold
Williams %R
94.802
Oversold
TRIX(12,20)
-0.547
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.609
Sell
MA10
0.630
Sell
MA20
0.687
Sell
MA50
0.662
Sell
MA100
0.704
Sell
MA200
1.105
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 2.90%, representing a quarter-over-quarter decrease of 74.01%. The largest institutional shareholder is James Simons, holding a total of 91.91K shares, representing 0.59% of shares outstanding, with 22.65% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
The Lind Partners, LLC
94.52K
-88.98%
Renaissance Technologies LLC
Star Investors
91.91K
+15.31%
Cambridge Investment Research Advisors, Inc.
77.26K
--
Swinford (Michael)
65.04K
--
Jasinski (Lawrence J)
61.42K
-0.49%
National Bank of Canada
39.24K
--
UBS Financial Services, Inc.
37.98K
+305.30%
Marshall (Robert J. Jr.)
35.92K
--
Turk (Joseph E Jr)
33.13K
--
Susquehanna International Group, LLP
31.92K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.64, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.64
Change
0
Beta vs S&P 500 index
0.01
VaR
+6.72%
240-Day Maximum Drawdown
+82.57%
240-Day Volatility
+144.67%

Return

Best Daily Return
60 days
+18.99%
120 days
+18.99%
5 years
+99.23%
Worst Daily Return
60 days
-14.64%
120 days
-36.80%
5 years
-36.80%
Sharpe Ratio
60 days
-0.62
120 days
-1.64
5 years
-0.34

Risk Assessment

Maximum Drawdown
240 days
+82.57%
3 years
+93.94%
5 years
+98.54%
Return-to-Drawdown Ratio
240 days
-0.83
3 years
-0.32
5 years
-0.20
Skewness
240 days
+0.26
3 years
+0.60
5 years
+4.32

Volatility

Realised Volatility
240 days
+144.67%
5 years
+101.73%
Standardised True Range
240 days
+23.93%
5 years
+89.99%
Downside Risk-Adjusted Return
120 days
-191.45%
240 days
-191.45%
Maximum Daily Upside Volatility
60 days
+61.08%
Maximum Daily Downside Volatility
60 days
+54.48%

Liquidity

Average Turnover Rate
60 days
+6.92%
120 days
+19.43%
5 years
--
Turnover Deviation
20 days
-65.87%
60 days
-2.20%
120 days
+174.41%

Peer Comparison

Healthcare Equipment & Supplies
Lifeward Ltd
Lifeward Ltd
LFWD
6.08 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI